Debra Byrne

P147 Safety and efficacy of ustekinumab for Crohn’s disease (CD): the cross pennine experience

Rachael C. Walker, C. Stansfield, C. Selinger, 2021, Posters.

A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II

A. de Silvestri, C. Stansfield, C. Selinger, 2021, Alimentary pharmacology & therapeutics.